{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:07:23Z","timestamp":1791119243294,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":4117,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1016\/j.bbmt.2003.09.013","type":"journal-article","created":{"date-parts":[[2004,1,14]],"date-time":"2004-01-14T05:12:21Z","timestamp":1074057141000},"page":"40-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect"],"prefix":"10.1016","volume":"10","author":[{"given":"Shoshana","family":"Morecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Yacovlev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vilensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2003.09.013_BIB1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/85.8.622","article-title":"Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer","volume":"85","author":"Rosenberg","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2003.09.013_BIB2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000204577","article-title":"Interleukin-2 +\/\u2212 lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies","volume":"89","author":"Fefer","year":"1993","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB3","first-page":"208","article-title":"Prevention of GVHD and induction of graft vs leukemia (GVL) effects","volume":"3","author":"Slavin","year":"1988","journal-title":"Bone Marrow Transplant."},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2003.09.013_BIB4","first-page":"566a","article-title":"Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT)","volume":"76","author":"Slavin","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB5","first-page":"1553","article-title":"Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes","volume":"23","author":"Slavin","year":"1995","journal-title":"Exp Hematol."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(01)00455-7","article-title":"Immunotherapy of cancer with alloreactive lymphocytes","volume":"2","author":"Slavin","year":"2001","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1015415928521","article-title":"Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice","volume":"22","author":"Verneris","year":"2002","journal-title":"J Clin Immunol."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB8","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.V94.4.1201","article-title":"Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes","volume":"94","author":"Falkenburg","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.bmt.1703223","article-title":"Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes","volume":"28","author":"Slavin","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","article-title":"Antileukemic effect of chronic graft- versus-host disease","volume":"304","author":"Weiden","year":"1981","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB13","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/152581602753658457","article-title":"Donor lymphocyte infusion","volume":"11","author":"Slavin","year":"2002","journal-title":"J Hematother Stem Cell Res."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB16","first-page":"153","article-title":"Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia","volume":"5","author":"Weiss","year":"1999","journal-title":"Cytokines Cell Mol Ther."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-065X.1997.tb00981.x","article-title":"The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation","volume":"157","author":"Murphy","year":"1997","journal-title":"Immunol Rev."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB18","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI1268","article-title":"Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation","volume":"101","author":"Asai","year":"1998","journal-title":"J Clin Invest."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00062752-200111000-00007","article-title":"Cellular therapy","volume":"8","author":"Ruggeri","year":"2001","journal-title":"Curr Opin Hematol."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB20","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Karre","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/1529-0131(200006)43:6<1204::AID-ANR3>3.0.CO;2-I","article-title":"Natural killer cells and natural killer T cells","volume":"43","author":"Seaman","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nrc928","article-title":"New aspects of natural-killer-cell surveillance and therapy of cancer","volume":"2","author":"Smyth","year":"2002","journal-title":"Nat Rev Cancer."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1056\/NEJM199103073241005","article-title":"Graft-versus-host disease","volume":"324","author":"Ferrara","year":"1991","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB25","first-page":"225","article-title":"Acute graft-versus-host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia","volume":"12","author":"Crawford","year":"1993","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB26","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.1998.16.3.986","article-title":"Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer","volume":"16","author":"Ueno","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB28","first-page":"3174","article-title":"Heterogeneity of tumor cells from a single mouse mammary tumor","volume":"38","author":"Dexter","year":"1978","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB29","first-page":"3891","article-title":"Allogeneic cell therapy for a murine mammary carcinoma","volume":"58","author":"Morecki","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/eji.1830050208","article-title":"\u201cNatural\u201d killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.bmt.1703118","article-title":"Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen","volume":"28","author":"Morecki","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB32","first-page":"1486","article-title":"Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines","volume":"58","author":"Pulaski","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00007890-198508000-00019","article-title":"Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation","volume":"40","author":"Morecki","year":"1985","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB35","first-page":"579","article-title":"A generalized Kruskal-Wallis test for comparing K sample subject to unequal patterns of censorship","volume":"57","author":"Breslow","year":"1970","journal-title":"Biomedika."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00002371-200103000-00005","article-title":"Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma","volume":"24","author":"Morecki","year":"2001","journal-title":"J Immunother."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1074-7613(00)80299-X","article-title":"The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts","volume":"4","author":"Yu","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB38","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","article-title":"Death receptors","volume":"281","author":"Ashkenazi","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2003.09.013_BIB39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.193.6.661","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis","volume":"193","author":"Smyth","year":"2001","journal-title":"J Exp Med."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0952-7915(02)00007-9","article-title":"Innate immune recognition by stimulatory immunoreceptors","volume":"15","author":"Diefenbach","year":"2003","journal-title":"Curr Opin Immunol."},{"key":"10.1016\/j.bbmt.2003.09.013_BIB41","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/blood.V97.10.3132","article-title":"Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo","volume":"97","author":"Koh","year":"2001","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879103003653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879103003653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:57:28Z","timestamp":1761055048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879103003653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S1083879103003653"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2003.09.013","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2003.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}